Interleukin 35

Structure

IL-35 and its receptor

IL-35 is a dimeric protein composed of IL-12α and IL-27β chains, which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr virus-induced gene 3), respectively. IL-35 receptor consists of IL-12Rβ2 (part of the IL-12R) and gp130 (part of IL-27R) chains. Compared to these two related interleukins, IL-35 is also able to signal through only one of the aforementioned chains. This was proven in vivo when absence of either of the receptor chains did not influence effects of IL-35. On regulatory B-cells, IL-35 signals through the IL-12Rβ2 and IL-27Rα subunits.

EBI3 is a homologue to IL-12 p40 and to the ciliary neurotrophic factor receptor, whose expression is induced in B lymphoblastoid cells by EBV infection

Function

Expression

Secreted by regulatory T-cells (Tregs), regulatory B-cells (Bregs) or even CD8+ regulatory T cells, IL-35 suppresses inflammatory responses of immune cells. IL-35 is not constitutively expressed in tissues, but the gene encoding IL-35 is transcribed by vascular endothelial cells, smooth muscle cells and monocytes after activation with proinflammatory stimuli. IL-35 has selective activities on different T-cell subsets; it induces proliferation of Treg cell populations but reduces activity of Th17 cell populations.

Role in disease

Autoimmune conditions

Studies in mice show the absence of either IL-35 chain from regulatory Tregs reduces the cells' ability to suppress inflammation. This has been observed during cell culture experiments and using an experimental model for inflammatory bowel disease. A group of scientists established a CIA (collagen-induced arthritis) mouse model to show suppressive effects of IL-35. Intraperitoneal injection of IL-35 in the tested subjects lowered expression of several factors linked to this disease (such as VEGF and its receptors, TNF-α). The effect of IL-35 in this case seems to be the inhibition of STAT1 signalling pathway. Another experiment performed on a mouse model of EAE has shown, that mice lacking IL-35-producing B cells are unable to recover from the T-cell mediated demyelination but are resistant to infection by pathogenic intracellular microbe Salmonella typhimurium. In T1D (type 1 diabetes), plasma level of IL-35 is lower than healthy individuals. IL-35 production by Tregs is decreased in mouse models of T1D, and administration of IL-35 prevents the development of experimental T1D and reverses established experimental T1D. In T1D patients with remaining C-peptide, IL-35 production by Tregs and Bregs is much higher than T1D patients with no remaining C-peptide.

Infectious diseases

It has been shown that IL-35 increases replication of HBV virus both in vitro and in transgenic mice by targeting its transcription factor HNF4α.

Tumor

Given its suppressive function, IL-35 is also involved in tumor progression and tumor immune surveillance. Elevated circulating IL-35 levels have been found in several human tumors such as acute myeloid leukemia, pancreatic ductal adenocarcinoma and colorectal cancer.

Moreover, Forkhead box protein 3 (Foxp3) as a transcription factor is an essential molecular marker of regulatory T (Treg) cells. Foxp3 polymorphism (rs3761548) might be involved in cancer progression like gastric cancer through influencing Tregs function and the secretion of immunomodulatory cytokines such as IL-10, IL-35, and TGF-β.

References

References

1. (March 2016). "IL-12 Family Cytokines: General Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways". Acta Microbiologica et Immunologica Hungarica.
2. (October 2019). "IL-35, as a newly proposed homeostasis-associated molecular pattern, plays three major functions including anti-inflammatory initiator, effector, and blocker in cardiovascular diseases". Cytokine.
3. (July 2018). "Emerging role of IL-35 in inflammatory autoimmune diseases". Autoimmunity Reviews.
4. (February 2012). "The composition and signaling of the IL-35 receptor are unconventional". Nature Immunology.
5. (June 2014). "Interleukin-35 induces regulatory B cells that suppress autoimmune disease". Nature Medicine.
6. (February 1996). "A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes". Journal of Virology.
7. (March 2014). "IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases". Nature.
8. (December 2012). "Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade". Journal of Immunology.
9. (March 2018). "IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (Histone 3 Lysine 14)". Arteriosclerosis, Thrombosis, and Vascular Biology.
10. (March 2012). "IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines". PLOS ONE.
11. (November 2007). "IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells". European Journal of Immunology.
12. (November 2007). "The inhibitory cytokine IL-35 contributes to regulatory T-cell function". Nature.
13. (May 2016). "Interleukin-35 attenuates collagen-induced arthritis through suppression of vascular endothelial growth factor and its receptors". International Immunopharmacology.
14. (March 2018). "Interleukin-35 inhibits angiogenesis through STAT1 signalling in rheumatoid synoviocytes". Clinical and Experimental Rheumatology.
15. (July 2012). "IL-12 family cytokines: immunological playmakers". Nature Immunology.
16. (October 2015). "Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease". Cytokine.
17. (July 2015). "Interleukin-35 administration counteracts established murine type 1 diabetes--possible involvement of regulatory T cells". Scientific Reports.
18. (August 2017). "Increased Interleukin-35 Levels in Patients With Type 1 Diabetes With Remaining C-Peptide". Diabetes Care.
19. (May 2018). "Interleukin-35 stimulates hepatitis B virus transcription and replication by targeting transcription factor HNF4α". The Journal of General Virology.
20. (July 2015). "Interleukin-35: Expanding Its Job Profile". Journal of Interferon & Cytokine Research.
21. (May 2012). "Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia". Oncology Letters.
22. (January 2014). "Circulating IL-35 in pancreatic ductal adenocarcinoma patients". Human Immunology.
23. (2013-08-15). "Assessing the role of IL-35 in colorectal cancer progression and prognosis". International Journal of Clinical and Experimental Pathology.
24. (February 2021). "Association of Foxp3 rs3761548 polymorphism with cytokines concentration in gastric adenocarcinoma patients". Cytokine.